54015-04-2

Basic information

• Product Name: N-P-TOLYL-GUANIDINE
• Synonyms: N-P-TOLYL-GUANIDINE;Guanidine, N-(4-methylphenyl)-;2-(4-methylphenyl)guanidine
• CAS NO: 54015-04-2
• Molecular Formula: C₈H₁₁N₃
• Molecular Weight: 149.19
• Mol File: 54015-04-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: N-P-TOLYL-GUANIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-P-TOLYL-GUANIDINE(54015-04-2)
• EPA Substance Registry System: N-P-TOLYL-GUANIDINE(54015-04-2)

Safety Data

• Hazardous Substances Data: 54015-04-2(Hazardous Substances Data)

Usage

General Description

N-P-Tolyl-guanidine, also known as PTG, is a organic compound that is commonly used as a rubber accelerator and antioxidant in the production of rubber products. It is a white to light yellow crystalline powder that is insoluble in water but soluble in benzene and chloroform. PTG is also used as an intermediate in the synthesis of pharmaceuticals and organic chemicals. It is known for its ability to improve the tensile and fatigue properties of rubber, making it a valuable additive in the manufacturing of tires, conveyor belts, and other rubber products. However, PTG should be handled with care as it may cause skin and eye irritation and can be harmful if ingested or inhaled.

Upstream product

• 420-04-2 CYANAMID 
• 32954-54-4 para-methyl anilinium nitrate 
• 106-49-0 p-toluidine 
• 540-23-8 p-toluidine hydrochloride 
• 97730-69-3 p-tolylguanidine carbonate 

Downstream Products

• 96238-98-1 5-Ethyl-4,6-dimethyl-2-(4-toluidino)pyrimidin 
• 170747-18-9 N-(6-chloro-1,1-dioxo-7-methyl-1,4,2-benzodithiazin-3-yl)-N'-(p-tolyl)guanidine 
• 170747-24-7 N-(6-chloro-1,1-dioxo-7-methoxycarbonyl-1,4,2-benzodithiazin-3-yl)-N'-(p-tolyl)guanidine 
• 1126642-78-1 3,5,6-trimethyl-N-(N-p-tolylcarbamimidoyl)pyrazine-2-carboxamide 
• 1610885-99-8 3,4-dimethyl-5-(2-(p-tolylamino)pyrimidin-4-yl)thiazol-2(3H)-one 
• 1415509-19-1 C₁₉H₁₇N₅ 
• 96717-15-6 4,6-Bis-(4-fluorphenyl)-2-(4-toluidino)pyrimidin 
• 96717-14-5 4-Trifluormethyl-6-(2-naphtyl)-2-(4-toluidino)pyrimidin 
• 96717-13-4 4-Trifluormethyl-6-phenyl-2-(4-toluidino)pyrimidin 

Relevant articles and documents

Discovery of CDK5 Inhibitors through Structure-Guided Approach

Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based in silico screenin

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation

Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumourigenesis and development. Targeting Mnks may provide a novel anticancer therapeutic strategy. However, the lack of selective Mnk inhibitors has so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino) pyrimidin-4-yl)thiazole-2(3H)-one derivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors. Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukaemia cells. Highly active Mnk2 inhibitors: Mnk-related cancer biology is an area of intensive research, but its inhibitor discovery has lagged behind due to a lack of understanding of the protein structure. Herein we report the discovery of Mnk2 inhibitors (e.g. 8 e). These potent and selective inhibitors are extremely valuable for target validation and drug discovery.

Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents

A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.